In search of a cure for PCOS
The SPIOMET4Health project


MMM is participating in an EU project, SPIOMET4Health, which aims at providing a treatment for Polycystic Ovary Syndrome (PCOS), a leading cause of infertility, while raising awareness about the prevalence of this hormonal disorder among young women.

About Polycystic Ovary Syndrome (PCOS) and its prevalence

Polycystic Ovary Syndrome (PCOS) is the leading cause of fertility problems in women. Indeed, it is negatively affecting the health and quality of life of approximately 110 million women globally in many ways. That’s between 5 and 10% of all women worldwide, and even of their offspring. It is the most common hormonal disorder among women of reproductive age. Women with PCOS may have a range of symptoms such as infrequent or prolonged menstrual periods, and excessive levels of male hormones (androgens); these are usually present in women in small amounts and may result in excessive body hair (hirsutism) and acne and also contribute to abnormal body fat distribution. PCOS is also associated with lifelong disorders such as type 2 Diabetes, premature vascular ageing, premenopausal cancer and a higher risk of premature birth in pregnancy.

These are symptoms that not only affect physical health but can have knock on effects on women’s confidence and self-esteem. Studies show that approximately 40% of women with PCOS are known to experience depression or anxiety. This emotional impact is also reinforced by the potential sub-fertility that PCOS can cause. PCOS not only has repercussions on the patient, but it also incurs a cost on society: it is estimated that its annual cost is approximately €23 billion in the European health sector. Currently, there is no approved treatment for Polycystic Ovary Syndrome (PCOS) in adolescent girls and young women

The EU project SPIOMET4HEALTH and MMM’s role

Therefore, the European Union’s Horizon 2020 research and innovation program is funding the SPIOMET4HEALTH project that aims to provide a new treatment for adolescent girls and young adult women with polycystic ovary syndrome.

MMM is participating in the European project as a communication partner, but also to alert politicians to the urgency of the situation. We hope that Europe can offer more funds to help young women suffering from this syndrome.

Our role is to spread the word about the importance of adolescent girls and young adult women aged 12 to 24, who suffer from PCOS, to come forward and participate in the project’s phase II clinical trial in different centers in Europe. The aim being to test whether this new therapeutic approach has the potential to improve the health-related quality of life for millions of women with PCOS.

Our goal?

Find a new treatment for SOPK: SPIOMET in a single tablet (SPI, 50 mg + PIO, 7.5 mg + MET, 850 mg) administered daily, together with specific lifestyle measures, aims to normalize ovulation and endocrine-metabolic status. SPIOMET4HEALTH will also impinge on the underlying mechanisms responsible for the development of PCOS and its results will serve as a basis for a Phase III clinical trial that will enable the exploitation of this novel approach throughout Europe.

This new treatment has the potential to become a preconception strategy that will likely be followed by spontaneous ovulation or conception, normal pregnancies, and a healthier next generation.

Learn more


Most read articles

In this together: Share the Care, Transform Tomorrow


UN New York, HLPF - Join us on July 11th for a discussion on how #SharingTheCare at every level - family, community, governments and private sector - is vital for

Lire plus

An almost Perfect Mother – New Podcast series with Isabelle Roskam


We are delighted to be launching our new podcast series An almost Perfect Mother featuring Isabelle Roskam, professor of development and parenting psychology at the University of Louvain, Belgium. Isa

Lire plus

Friendship NGO at the forefront of the fight against climate change


Our associate member in Bangladesh, Friendship NGO, responds to the call for input into an upcoming UN report on Human Rights and Climate Change.

Lire plus
See all the articlesof the category

News from the MMM European Delegation

MMM Response to the EU Care Strategy


We need care when we are very young or very old, experiencing sickness or disability and the people who provide this care are indispensable actors in European economies and societies.

Read more

In search of a cure for PCOS
The SPIOMET4Health project


MMM is participating in an EU project, SPIOMET4Health, which aims at providing a treatment for Polycystic Ovary Syndrome (PCOS), a leading cause of infertility, while raising awareness about the prevalence of t

Read more

Our member in Romania acts for Ukraine mothers & children


The ongoing conflict and resulting humanitarian crisis in Ukraine has had a devastating impact on the mental and physical health of mothers and their children, on both those who have fled and those who have sta

Read more

MMM contributes to EU Care Strategy


In these unprecedented times, when Europe is navigating a global pandemic, when political tensions are boiling over threatening to destabilize the global order, it is vital to reflect on the people who hold the

Read more

MMM connects gender pension gap and mothers’ ability to receive long term care in old age


Our contribution to the EU Commission's Call for evidence: “Access to affordable and high-quality long-term care” The COVID-19 pandemic has highlighted the need to strengthen the European care economy. To e

Read more

An integrated approach to childcare services from a children’s rights perspective


The European Commission (EC) has announced its new plan to develop a European Care Strategy expected to strengthen long-term care and early childhood education and care, as envisaged under the European pillar o

Read more